MedTrace Logo

Beta2-adrenergic Agonism and Muscle Remodelling

NCT03565302 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2020-03-25

No results posted yet for this study

Summary

The study aims to investigate gender-specific adaptations to beta2-adrenoceptor stimulation with selective short- and long-acting beta2-agonist with emphasis on skeletal muscle in relation to performance enhancing effects and anti-doping

Conditions

  • Hypertrophy
  • Physiologic Hypertrophy
  • Physical Activity

Interventions

DRUG

Formoterol

Subjects are treated with daily inhalation of formoterol

DRUG

Terbutaline

Subjects are treated with daily inhalation of terbutaline

OTHER

Placebo

Subjects are treated with placebo

Sponsors & Collaborators

  • Morten Hostrup, PhD

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-25
Primary Completion
2021-05-30
Completion
2021-05-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03565302 on ClinicalTrials.gov